Ardeschir Ghofrani

List of Publications by Year in Descending Order

460 papers	40,487 citations	87 h-index	191 g-index
580 ext. papers	48,601 ext. citations	8.4 avg, IF	6.91 L-index

#	Paper	IF	Citations
460	Childhood Trauma in Patients With PAH-Prevalence, Impact on QoL, and Mental Health-A Preliminary Report.. *Frontiers in Psychiatry*, **2022**, 13, 812862	5	
459	Childhood Maltreatment, Mental Well-Being, and Healthy Lifestyle in Patients With Chronic Thromboembolic Pulmonary Hypertension.. *Frontiers in Psychiatry*, **2022**, 13, 821468	5	1
458	Relevance of Cor Pulmonale in COPD With and Without Pulmonary Hypertension: A Retrospective Cohort Study.. *Frontiers in Cardiovascular Medicine*, **2022**, 9, 826369	5.4	0
457	Prevalence of Mental Disorders in Patients With Chronic Thromboembolic Pulmonary Hypertension.. *Frontiers in Psychiatry*, **2022**, 13, 821466	5	2
456	Metacognitions in Patients With Frequent Mental Disorders After Diagnosis of Pulmonary Arterial Hypertension.. *Frontiers in Psychiatry*, **2022**, 13, 812812	5	
455	Impact of Pulmonary Arterial Hypertension on Employment, Work Productivity, and Quality of Life - Results of a Cross-Sectional Multi-Center Study.. *Frontiers in Psychiatry*, **2021**, 12, 781532	5	1
454	Clinical Relevance of Right Atrial Functional Response to Treatment in Pulmonary Arterial Hypertension.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 775039	5.4	1
453	ERS statement on chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	70
452	COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension. *European Respiratory Journal*, **2021**,	13.6	7
451	Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry. *European Respiratory Journal*, **2021**,	13.6	6
450	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. *Pulmonary Circulation*, **2021**, 11, 20458940211057071	2.7	3
449	Reply to "Risk stratification in PH associated with interstitial lung disease: The Holy Grail?". *Journal of Heart and Lung Transplantation*, **2021**, 40, 317	5.8	
448	Validity of echocardiographic tricuspid regurgitation gradient to screen for new definition of pulmonary hypertension. *EClinicalMedicine*, **2021**, 34, 100822	11.3	3
447	Prevalence of Mental Disorders and Impact on Quality of Life in Patients With Pulmonary Arterial Hypertension. *Frontiers in Psychiatry*, **2021**, 12, 667602	5	13
446	Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. *Blood*, **2021**, 137, 2681-2693	2.2	3
445	Right ventricular pressure-volume loop shape and systolic pressure change in pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2021**, 320, L715-L725	5.8	4
444	Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. *Lancet Respiratory Medicine,the*, **2021**, 9, 573-584	35.1	22

443	Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart. *Clinical Research in Cardiology*, **2021**, 1	6.1	0
442	Impact of SARS-CoV-2-Pandemic on Mental Disorders and Quality of Life in Patients With Pulmonary Arterial Hypertension. *Frontiers in Psychiatry*, **2021**, 12, 668647	5	4
441	Amelioration of elastase-induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice. *British Journal of Pharmacology*, **2021**, 178, 152-171	8.6	2
440	Current and future treatments of pulmonary arterial hypertension. *British Journal of Pharmacology*, **2021**, 178, 6-30	8.6	42
439	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. *European Respiratory Journal*, **2021**, 57,	13.6	3
438	Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives. *ESC Heart Failure*, **2021**, 8, 183-203	3.7	11
437	Right heart failure in pulmonary hypertension: Diagnosis and new perspectives on vascular and direct right ventricular treatment. *British Journal of Pharmacology*, **2021**, 178, 90-107	8.6	17
436	Pulmonary Hypertension in Acute and Chronic High Altitude Maladaptation Disorders. *International Journal of Environmental Research and Public Health*, **2021**, 18,	4.6	7
435	A novel non-invasive and echocardiography-derived method for quantification of right ventricular pressure-volume loops. *European Heart Journal Cardiovascular Imaging*, **2021**,	4.1	3
434	PINK1-mediated Mitophagy Contributes to Pulmonary Vascular Remodeling in Pulmonary Hypertension. *American Journal of Respiratory Cell and Molecular Biology*, **2021**, 65, 226-228	5.7	1
433	Deficiency of Axl aggravates pulmonary arterial hypertension via BMPR2. *Communications Biology*, **2021**, 4, 1002	6.7	
432	Osteopontin and galectin-3 as biomarkers of maladaptive right ventricular remodeling in pulmonary hypertension. *Biomarkers in Medicine*, **2021**, 15, 1021-1034	2.3	1
431	Exercise Hemodynamic Profiling Is Associated With Outcome in Patients Undergoing Percutaneous Mitral Valve Repair. *Circulation: Cardiovascular Interventions*, **2021**, 14, e010453	6	1
430	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. *European Respiratory Review*, **2021**, 30,	9.8	6
429	Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.. *Cardiovascular Diagnosis and Therapy*, **2021**, 11, 1255-1268	2.6	0
428	Altered proteasome function in right ventricular hypertrophy. *Cardiovascular Research*, **2020**, 116, 406-415	9.9	5
427	Physical Activity and Mental Health of Patients with Pulmonary Hypertension during the COVID-19 Pandemic. *Journal of Clinical Medicine*, **2020**, 9,	5.1	4
426	Genetic Deletion of p66shc and/or Cyclophilin D Results in Decreased Pulmonary Vascular Tone. *Cardiovascular Research*, **2020**,	9.9	2

425	Evaluation of pulmonary hypertension by right heart catheterisation: does timing matter?. *European Respiratory Journal*, **2020**, 56,	13.6	4
424	A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 56,	13.6	14
423	Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. *Journal of Clinical Medicine*, **2020**, 9,	5.1	8
422	Sex Differences in Right Ventricular-Pulmonary Arterial Coupling in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1042-1046	10.2	19
421	Influence of gender in monocrotaline and chronic hypoxia induced pulmonary hypertension in obese rats and mice. *Respiratory Research*, **2020**, 21, 136	7.3	4
420	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. *Nature Metabolism*, **2020**, 2, 532-546	14.6	4
419	Cytochrome P450 epoxygenase-derived 5,6-epoxyeicosatrienoic acid relaxes pulmonary arteries in normoxia but promotes sustained pulmonary vasoconstriction in hypoxia. *Acta Physiologica*, **2020**, 230, e13521	5.6	4
418	is a Promising Therapeutic Option for Treatment of Pulmonary Hypertension due to the Potent Anti-Proliferative and Vasorelaxant Properties. *Medicina (Lithuania)*, **2020**, 56,	3.1	1
417	Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension. *Pulmonary Circulation*, **2020**, 10, 2045894020910136	2.7	5
416	FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction. *Basic Research in Cardiology*, **2020**, 115, 17	11.8	14
415	Right ventricular dyssynchrony: from load-independent right ventricular function to wall stress in severe pulmonary arterial hypertension. *Pulmonary Circulation*, **2020**, 10, 2045894020925759	2.7	3
414	SPARCL1 as a biomarker of maladaptive right ventricular remodelling in pulmonary hypertension. *Biomarkers*, **2020**, 25, 290-295	2.6	1
413	Association of right atrial conduit phase with right ventricular lusitropic function in pulmonary hypertension. *International Journal of Cardiovascular Imaging*, **2020**, 36, 633-642	2.5	7
412	Right ventricular function correlates of right atrial strain in pulmonary hypertension: a combined cardiac magnetic resonance and conductance catheter study. *American Journal of Physiology - Heart and Circulatory Physiology*, **2020**, 318, H156-H164	5.2	18
411	Advanced risk stratification of intermediate risk group in pulmonary arterial hypertension. *Pulmonary Circulation*, **2020**, 10, 2045894020961739	2.7	5
410	IRAG1 Deficient Mice Develop PKG1Dependent Pulmonary Hypertension. *Cells*, **2020**, 9,	7.9	2
409	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. *Pulmonary Circulation*, **2020**, 10, 2045894020947283	2.7	2
408	Impact of SARS-CoV-2 pandemic on pulmonary hypertension out-patient clinics in Germany: a multi-centre study. *Pulmonary Circulation*, **2020**, 10, 2045894020941682	2.7	9

407	Risk assessment in severe pulmonary hypertension due to interstitial lung disease. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1118-1125	5.8	6
406	Genetic Deficiency and Pharmacological Stabilization of Mast Cells Ameliorate Pressure Overload-Induced Maladaptive Right Ventricular Remodeling in Mice. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
405	Evaluation and Prognostic Relevance of Right Ventricular-Arterial Coupling in Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 116-119	10.2	30
404	Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. *Science Advances*, **2020**, 6, eaba0694	14.3	18
403	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. *Frontiers in Cardiovascular Medicine*, **2020**, 7, 51	5.4	4
402	Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1550-1554	10.2	2
401	Pulmonary Vascular Pressure Response to Acute Cold Exposure in Kyrgyz Highlanders. *High Altitude Medicine and Biology*, **2019**, 20, 375-382	1.9	2
400	Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. *Circulation: Cardiovascular Imaging*, **2019**, 12, e009047	3.9	77
399	Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension. *European Respiratory Journal*, **2019**, 54,	13.6	13
398	Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension. *Respiratory Research*, **2019**, 20, 208	7.3	8
397	Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases. *Circulation: Cardiovascular Quality and Outcomes*, **2019**, 12, e005095	5.8	5
396	Cardiopulmonary haemodynamics in portopulmonary hypertension. *Lancet Respiratory Medicine,the* , **2019**, 7, 556-558	35.1	1
395	Intravenous treprostinil as an add-on therapy in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2019**, 38, 748-756	5.8	13
394	Right ventricular function in pulmonary (arterial) hypertension. *Herz*, **2019**, 44, 509-516	2.6	8
393	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. *Nature Communications*, **2019**, 10, 2204	17.4	39
392	A simple echocardiographic estimate of right ventricular-arterial coupling to assess severity and outcome in pulmonary hypertension on chronic lung disease. *European Respiratory Journal*, **2019**, 54,	13.6	13
391	Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 515-518	10.2	13
390	Circulating Apoptotic Signals During Acute and Chronic Exposure to High Altitude in Kyrgyz Population. *Frontiers in Physiology*, **2019**, 10, 54	4.6	3

389	Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. *Cardiovascular Research*, **2019**, 115, 1217-1227	9.9	12
388	Cardiac Magnetic Resonance Imaging-Based Right Ventricular Strain Analysis for Assessment of Coupling and Diastolic Function in Pulmonary Hypertension. *JACC: Cardiovascular Imaging*, **2019**, 12, 2155-2164	8.4	36
387	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. *Circulation*, **2019**, 139, 2440-2450	16.7	32
386	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. *European Respiratory Journal*, **2019**, 53,	13.6	15
385	Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	32
384	Reply to "a pediatric perspective on the TAPSE/PASP ratio in pulmonary arterial hypertension". *International Journal of Cardiology*, **2019**, 278, 240-241	3.2	1
383	Reply to Bogaard : Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1450-1452	10.2	4
382	Enhanced circulating levels of CD3 cells-derived extracellular vesicles in different forms of pulmonary hypertension. *Pulmonary Circulation*, **2019**, 9, 2045894019864357	2.7	7
381	Acute response to rapid iloprost inhalation using the Breelib□nebulizer in pulmonary arterial hypertension: the Breelib□acute study. *Pulmonary Circulation*, **2019**, 9, 2045894019875342	2.7	3
380	Response by Tello et al to Letter Regarding Article, "Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension". *Circulation: Cardiovascular Imaging*, **2019**, 12, e010059	3.9	7
379	Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. *Lancet Respiratory Medicine,the*, **2019**, 7, 227-238	35.1	55
378	Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1407-1420	10.2	25
377	Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension-related hospitalization in the AMBITION trial. *Journal of Heart and Lung Transplantation*, **2019**, 38, 194-202	5.8	9
376	Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?. *Lancet Respiratory Medicine,the*, **2019**, 7, 191-193	35.1	1
375	Multibeat Right Ventricular-Arterial Coupling during a Positive Acute Vasoreactivity Test. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, e41-e42	10.2	8
374	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. *European Journal of Heart Failure*, **2019**, 21, 352-359	12.3	26
373	Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. *Circulation: Heart Failure*, **2019**, 12, e005512	7.6	78
372	Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. *Pulmonary Circulation*, **2019**, 9, 2045894018805406	2.7	23

371	Chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2019**, 53,	13.6	263
370	Nitric Oxide Synthase 2 Induction Promotes Right Ventricular Fibrosis. *American Journal of Respiratory Cell and Molecular Biology*, **2019**, 60, 346-356	5.7	14
369	EXPRESS: Switching to riociguat: A potential treatment strategy for the management of CTEPH and PAH. *Pulmonary Circulation*, **2019**, 2045894019837849	2.7	1
368	REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat. *Journal of Heart and Lung Transplantation*, **2018**, 37, 836-843	5.8	14
367	Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. *Nature Communications*, **2018**, 9, 1416	17.4	182
366	Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data. *Scientific Reports*, **2018**, 8, 1300	4.9	33
365	Impact of the mitochondria-targeted antioxidant MitoQ on hypoxia-induced pulmonary hypertension. *European Respiratory Journal*, **2018**,	13.6	30
364	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. *Journal of the American College of Cardiology*, **2018**, 71, 752-763	15.1	50
363	Measures of subclinical cardiac dysfunction and increased filling pressures associate with pulmonary arterial pressure in the general population: results from the population-based Rotterdam Study. *European Journal of Epidemiology*, **2018**, 33, 403-413	12.1	3
362	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. *American Journal of Cardiovascular Drugs*, **2018**, 18, 37-47	4	39
361	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. *Pulmonary Circulation*, **2018**, 8, 2045893217753122	2.7	39
360	Beyond interleukin-6 in right ventricular function: Evidence for another biomarker. *Journal of Heart and Lung Transplantation*, **2018**, 37, 674-675	5.8	2
359	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. *BMC Pulmonary Medicine*, **2018**, 18, 41	3.5	31
358	Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies. *Pulmonary Circulation*, **2018**, 8, 2045894018769305	2.7	14
357	Short-term venoarterial extracorporeal membrane oxygenation for massive endobronchial hemorrhage after pulmonary endarterectomy. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 155, 643-649	1.5	17
356	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. *Journal of Heart and Lung Transplantation*, **2018**, 37, 401-408	5.8	12
355	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 373-385	10.2	57
354	Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers. *Frontiers in Physiology*, **2018**, 9, 609	4.6	26

353	Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial. *Pulmonary Circulation*, **2018**, 8, 2045894018798921	2.7	4
352	Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. *International Journal of Cardiology*, **2018**, 266, 229-235	3.2	65
351	Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. *PLoS ONE*, **2018**, 13, e0193226	3.7	17
350	REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. *Journal of Heart and Lung Transplantation*, **2018**, 37, 513-519	5.8	22
349	Response to: Comment on "Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding". *BioMed Research International*, **2018**, 2018, 7491284	3	
348	Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study). *Respiratory Research*, **2018**, 19, 258	7.3	21
347	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. *Circulation: Cardiovascular Imaging*, **2018**, 11, e007653	3.9	5
346	Targeted therapy of pulmonary arterial hypertension: Updated recommendations from the Cologne Consensus Conference 2018. *International Journal of Cardiology*, **2018**, 272S, 37-45	3.2	33
345	Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease. *European Respiratory Journal*, **2018**, 52,	13.6	29
344	Nintedanib in Severe Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 808-810	10.2	11
343	More on Single-Beat Estimation of Right Ventriculoarterial Coupling in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 816-818	10.2	45
342	De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with Seizures. *American Journal of Human Genetics*, **2018**, 103, 144-153	11	18
341	Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. *BioMed Research International*, **2018**, 2018, 3293584	3	17
340	Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels. *Experimental Physiology*, **2018**, 103, 1185-1191	2.4	7
339	Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. *Pulmonary Circulation*, **2018**, 8, 2045894018783996	2.7	31
338	Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2018**, 37, 1235-1244	5.8	16
337	The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension. *Clinical Respiratory Journal*, **2017**, 11, 682-690	1.7	5
336	Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. *Chest*, **2017**, 151, 468-480	5.9	57

335	Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. *Journal of Heart and Lung Transplantation*, **2017**, 36, 509-519	5.8	16
334	The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups. *Journal of Heart and Lung Transplantation*, **2017**, 36, 957-967	5.8	138
333	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. *Annals of the Rheumatic Diseases*, **2017**, 76, 1219-1227	2.4	96
332	Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. *Journal of Heart and Lung Transplantation*, **2017**, 36, 880-889	5.8	10
331	Amplified canonical transforming growth factor-β signalling heat shock protein 90 in pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	43
330	Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2. *Annals of the Rheumatic Diseases*, **2017**, 76, 422-426	2.4	76
329	Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension. *Heart*, **2017**, 103, 599-606	5.1	19
328	Intravenous treprostinil infusion via a fully implantable pump for pulmonary arterial hypertension. *Clinical Research in Cardiology*, **2017**, 106, 776-783	6.1	17
327	Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study. *Respiratory Medicine*, **2017**, 128, 50-56	4.6	25
326	Inspiratory capacity is not altered in operable chronic thromboembolic pulmonary hypertension. *Pulmonary Circulation*, **2017**, 7, 543-546	2.7	2
325	Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. *Lancet Respiratory Medicine,the*, **2017**, 5, 717-726	35.1	62
324	Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing. *Circulation Research*, **2017**, 121, 424-438	15.7	58
323	Plasma MMP2/TIMP4 Ratio at Follow-up Assessment Predicts Disease Progression of Idiopathic Pulmonary Arterial Hypertension. *Lung*, **2017**, 195, 489-496	2.9	10
322	Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study. *European Respiratory Journal*, **2017**, 49,	13.6	20
321	Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Respiratory Medicine*, **2017**, 129, 124-129	4.6	9
320	Effects of exercise training on pulmonary hemodynamics, functional capacity and inflammation in pulmonary hypertension. *Pulmonary Circulation*, **2017**, 7, 20-37	2.7	21
319	Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience. *European Respiratory Journal*, **2017**, 49,	13.6	111
318	The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension. *Pulmonary Circulation*, **2017**, 7, 505-513	2.7	14

317	Medical management of chronic thromboembolic pulmonary hypertension. *European Respiratory Review*, **2017**, 26,	9.8	41
316	Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension. *European Respiratory Review*, **2017**, 26,	9.8	130
315	Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice. *Experimental Physiology*, **2017**, 102, 180-189	2.4	14
314	Pulmonary function and diffusion capacity are associated with pulmonary arterial systolic pressure in the general population: The Rotterdam Study. *Respiratory Medicine*, **2017**, 132, 50-55	4.6	3
313	Thin Air Resulting in High Pressure: Mountain Sickness and Hypoxia-Induced Pulmonary Hypertension. *Canadian Respiratory Journal*, **2017**, 2017, 8381653	2.1	19
312	Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle. *Physiological Reports*, **2017**, 5, e13146	2.6	30
311	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	58
310	Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2017**, 5, 785-794	35.1	133
309	RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. *European Respiratory Journal*, **2017**, 50,	13.6	74
308	Tidal Carbon Dioxide as a Prognostic Feature in Inoperable Chronic Thromboembolic Pulmonary Hypertension. *Annals of the American Thoracic Society*, **2017**, 14, 1603-1604	4.7	
307	Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. *European Respiratory Journal*, **2017**, 50,	13.6	288
306	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. *Science Translational Medicine*, **2017**, 9,	17.5	50
305	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. *American Journal of Respiratory Cell and Molecular Biology*, **2017**, 57, 603-614	5.7	48
304	Macitentan Improves Health-Related Quality´of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial. *Chest*, **2017**, 151, 106-118	5.3	36
303	Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension. *Clinical Research in Cardiology*, **2017**, 106, 174-182	6.1	14
302	Therapie der pulmonal arteriellen Hypertonie. *Klinikarzt*, **2017**, 46, 374-381	0	
301	SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. *European Heart Journal*, **2017**, 38, 1147-1155	9.5	44
300	The Role of Transient Receptor Potential Channel 6 Channels in the Pulmonary Vasculature. *Frontiers in Immunology*, **2017**, 8, 707	8.4	29

299	Follow-Up (Measurement) of Corrected QT Interval in Adult Patients before and after Lung Transplantation. *BioMed Research International*, **2017**, 2017, 4519796	3	0
298	Macitentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): results from the randomised controlled MERIT study **2017**,		7
297	Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension. *Oncotarget*, **2017**, 8, 29613-29624	3.3	6
296	Pulmonary Hypertension. *Deutsches Ärzteblatt International*, **2017**, 114, 73-84	2.5	57
295	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	9.5	3455
294	Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension. *International Journal of Cardiology*, **2016**, 223, 821-826	3.2	18
293	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. *Journal of Thrombosis and Thrombolysis*, **2016**, 42, 600-9	5.1	29
292	The prognostic impact of thyroid function in pulmonary hypertension. *Journal of Heart and Lung Transplantation*, **2016**, 35, 1427-1434	5.8	14
291	Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study. *BMC Pulmonary Medicine*, **2016**, 16, 5	3.5	8
290	Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. *International Journal of Cardiology*, **2016**, 216, 85-91	3.2	20
289	Prolonged vasodilatory response to nanoencapsulated sildenafil in pulmonary hypertension. *Nanomedicine: Nanotechnology, Biology, and Medicine*, **2016**, 12, 63-8	6	13
288	Effects of carbon monoxide-releasing molecules on pulmonary vasoreactivity in isolated perfused lungs. *Journal of Applied Physiology*, **2016**, 120, 271-81	3.7	7
287	miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. *Cardiovascular Research*, **2016**, 111, 184-93	9.9	42
286	2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 177	0.7	148
285	Gu□ ESC/ERS 2015 sobre diagn□tico y tratamiento de la hipertensi□ pulmonar. *Revista Espanola De Cardiologia*, **2016**, 69, 177.e1-177.e62	1.5	137
284	The molecular targets of approved treatments for pulmonary arterial hypertension. *Thorax*, **2016**, 71, 73-83	7.3	87
283	The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension. *PLoS ONE*, **2016**, 11, e0152580	3.7	8
282	Circulating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary Hypertension. *PLoS ONE*, **2016**, 11, e0165982	3.7	5

281	2015 ESC/ERS GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION. *Russian Journal of Cardiology*, **2016**, 5-64	1.3	10
280	Evaluation of the prognostic value of electrocardiography parameters and heart rhythm in patients with pulmonary hypertension. *Cardiology Journal*, **2016**, 23, 465-72	1.4	18
279	Prognostic Relevance of Nonsustained Ventricular Tachycardia in Patients with Pulmonary Hypertension. *BioMed Research International*, **2016**, 2016, 1327265	3	6
278	Heart rate response during 6-minute walking testing predicts outcome in operable chronic thromboembolic pulmonary hypertension. *BMC Pulmonary Medicine*, **2016**, 16, 96	3.5	4
277	Quality of life in patients with chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2016**, 48, 526-37	13.6	34
276	Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy. *Pulmonary Circulation*, **2016**, 6, 516-523	2.7	5
275	COPD-associated pulmonary hypertension: clinical implications and current methods for treatment. *Expert Review of Respiratory Medicine*, **2016**, 10, 755-66	3.8	4
274	Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 361-71	35.1	69
273	Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. *Lancet Respiratory Medicine,the*, **2016**, 4, 372-80	35.1	98
272	Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study. *Lancet Respiratory Medicine,the*, **2016**, 4, 894-901	35.1	37
271	Selexipag for the treatment of pulmonary arterial hypertension. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 1825-34	4	2
270	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. *European Journal of Heart Failure*, **2016**, 18, 482-9	12.3	49
269	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 48, 1137-1149	13.6	57
268	Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. *Pulmonary Circulation*, **2015**, 5, 162-70	2.7	11
267	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. *Pulmonary Circulation*, **2015**, 5, 305-12	2.7	13
266	Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the phase III PATENT-1 study. *Journal of Heart and Lung Transplantation*, **2015**, 34, 338-47	5.8	9
265	Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. *Journal of Heart and Lung Transplantation*, **2015**, 34, 348-55	5.8	11
264	Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease. *Pulmonary Circulation*, **2015**, 5, 296-304	2.7	26

263	Pulmonary Hemodynamic Response to Exercise in Chronic Thromboembolic Pulmonary Hypertension before and after Pulmonary Endarterectomy. *Respiration*, **2015**, 90, 63-73	3.7	18
262	Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 46, 405-13	13.6	136
261	Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis. *European Respiratory Journal*, **2015**, 46, 1084-94	13.6	29
260	Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study. *Journal of Heart and Lung Transplantation*, **2015**, 34, S163	5.8	2
259	Poor sleep quality is associated with exercise limitation in precapillary pulmonary hypertension. *BMC Pulmonary Medicine*, **2015**, 15, 11	3.5	4
258	Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study. *Herzschrittmachertherapie Und Elektrophysiologie*, **2015**, 26, 155-62	0.8	9
257	New potential diagnostic biomarkers for pulmonary hypertension. *European Respiratory Journal*, **2015**, 46, 1390-6	13.6	22
256	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung	13.6	1672
255	Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2015**, 373, 834-44	59.2	618
254	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). *European Respiratory Journal*, **2015**, 45, 1293-302	13.6	175
253	Effect of macitentan on hospitalizations: results from the SERAPHIN trial. *JACC: Heart Failure*, **2015**, 3, 1-8	7.9	42
252	Resistant hypertension: medical management and alternative therapies. *Cardiology Clinics*, **2015**, 33, 75-87	2.5	7
251	Individualized Dosing of Selexipag Based on Tolerability in the GRIPHON Study Shows Consistent Efficacy and Safety in Patients With Pulmonary Arterial Hypertension (PAH). *Chest*, **2015**, 148, 961A	5.3	3
250	Riociguat in Combination With Prostacyclin Analogs for the Treatment of Pulmonary Arterial Hypertension (PAH): A Subgroup Analysis of the PATENT Studies. *Chest*, **2015**, 148, 922A	5.3	2
249	Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. *European Respiratory Journal*, **2015**, 46, 1711-20	13.6	31
248	Heart Rate Variability is Related to Disease Severity in Children and Young Adults with Pulmonary Hypertension. *Frontiers in Pediatrics*, **2015**, 3, 63	3.4	9
247	5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure. *BioMed Research International*, **2015**, 2015, 438403	3	48
246	Riociguat for pulmonary arterial hypertension associated with congenital heart disease. *Heart*, **2015**, 101, 1792-9	5.1	64

245	Selexipag for the Treatment of Pulmonary Arterial Hypertension. *New England Journal of Medicine*, **2015**, 373, 2522-33	59.2	521
244	Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2015**, 34, 1366-75	5.8	72
243	Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). *European Respiratory Journal*, **2015**, 45, 1303-13	13.6	131
242	Pathophysiology and treatment of high-altitude pulmonary vascular disease. *Circulation*, **2015**, 131, 582-90	16.7	70
241	Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population **2015**,		2
240	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. *PLoS ONE*, **2015**, 10, e0129327	3.7	24
239	Prevalence of Pulmonary Hypertension in the General Population: The Rotterdam Study. *PLoS ONE*, **2015**, 10, e0130072	3.7	41
238	Impact of S-adenosylmethionine decarboxylase 1 on pulmonary vascular remodeling. *Circulation*, **2014**, 129, 1510-23	16.7	17
237	Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 808-17	10.2	129
236	Novel and emerging therapies for pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 394-400	10.2	62
235	Long-term Riociguat Treatment in PAH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 12-Week Phase III PATENT-1 Study and PATENT-2 Open-Label Extension. *Chest*, **2014**, 145, 513A	5.3	3
234	Long-term Riociguat Treatment in Inoperable and Persistent/Recurrent CTEPH Patients in WHO Functional Class (FC) I/II Versus FC III/IV at Baseline: Results From the 16-Week Phase III CHEST-1 Study and CHEST-2 Open-Label Extension. *Chest*, **2014**, 145, 535B	5.3	4
233	Response to letters regarding article, "Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA)". *Circulation*, **2014**, 130, e110-2	16.7	4
232	Electrophysiological studies in patients with pulmonary hypertension: a retrospective investigation. *BioMed Research International*, **2014**, 2014, 617565	3	9
231	Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease. *Pulmonary Circulation*, **2014**, 4, 128-36	2.7	26
230	Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA). *Circulation*, **2014**, 129, 57-65	16.7	235
229	Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 1359-73	10.2	59
228	Structural and functional prevention of hypoxia-induced pulmonary hypertension by individualized exercise training in mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2014**, 306, L986-95	5.8	25

227	The role of combination therapy in managing pulmonary arterial hypertension. *European Respiratory Review*, **2014**, 23, 469-75	9.8	35
226	Arterial hypertension in a murine model of sleep apnea: role of NADPH oxidase 2. *Journal of Hypertension*, **2014**, 32, 300-5	1.9	41
225	The prognostic significance of inspiratory capacity in pulmonary arterial hypertension. *Respiration*, **2014**, 88, 24-30	3.7	12
224	Interaction of ambrisentan and phenprocoumon in patients with pulmonary hypertension. *Pulmonary Pharmacology and Therapeutics*, **2014**, 28, 87-89	3.5	6
223	Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *New England Journal of Medicine*, **2013**, 369, 319-29	59.2	852
222	Riociguat for the treatment of pulmonary arterial hypertension. *New England Journal of Medicine*, **2013**, 369, 330-40	59.2	861
221	Mitochondrial hyperpolarization in pulmonary vascular remodeling. Mitochondrial uncoupling protein deficiency as disease model. *American Journal of Respiratory Cell and Molecular Biology*, **2013**, 49, 358-67	5.7	50
220	Macitentan and morbidity and mortality in pulmonary arterial hypertension. *New England Journal of Medicine*, **2013**, 369, 809-18	59.2	878
219	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. *International Journal of Cardiology*, **2013**, 167, 2630-7	3.2	29
218	Updated clinical classification of pulmonary hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D34-41	15.1	1937
217	Function of NADPH oxidase 1 in pulmonary arterial smooth muscle cells after monocrotaline-induced pulmonary vascular remodeling. *Antioxidants and Redox Signaling*, **2013**, 19, 2213-31	8.4	57
216	Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. *Circulation*, **2013**, 128, 502-11	16.7	215
215	Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. *Circulation*, **2013**, 127, 1128-38	16.7	368
214	Cofilin, a hypoxia-regulated protein in murine lungs identified by 2DE: role of the cytoskeletal protein cofilin in pulmonary hypertension. *Proteomics*, **2013**, 13, 75-88	4.8	14
213	New trial designs and potential therapies for pulmonary artery hypertension. *Journal of the American College of Cardiology*, **2013**, 62, D82-91	15.1	90
212	Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. *International Journal of Cardiology*, **2013**, 168, 871-80	3.2	231
211	Riociguat for pulmonary hypertension. *New England Journal of Medicine*, **2013**, 369, 2268	59.2	13
210	Sleep apnea in precapillary pulmonary hypertension. *Sleep Medicine*, **2013**, 14, 247-51	4.6	58

209	Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 294-302	10.2	126
208	Effects of dimethylarginine dimethylaminohydrolase-1 overexpression on the response of the pulmonary vasculature to hypoxia. *American Journal of Respiratory Cell and Molecular Biology*, **2013**, 49, 491-500	5.7	15
207	New horizons in pulmonary arterial hypertension therapies. *European Respiratory Review*, **2013**, 22, 503-14	3.8	29
206	Classical transient receptor potential channel 1 in hypoxia-induced pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 1451-9	10.2	58
205	Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. *Respiratory Research*, **2013**, 14, 104	7.3	64
204	Updating clinical endpoint definitions. *Pulmonary Circulation*, **2013**, 3, 206-16	2.7	19
203	Short-term improvement in pulmonary hemodynamics is strongly predictive of long-term survival in patients with pulmonary arterial hypertension. *Pulmonary Circulation*, **2013**, 3, 523-32	2.7	18
202	Riociguat for the Treatment of Pulmonary Arterial Hypertension (PAH): 1-Year Results from the PATENT-2 Long-term Extension Study. *Chest*, **2013**, 144, 1024A	5.3	3
201	Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): 1-Year Results from the CHEST-2 Long-term Extension Study. *Chest*, **2013**, 144, 1023A	5.3	3
200	Mast cell chymase: an indispensable instrument in the pathological symphony of idiopathic pulmonary fibrosis?. *Histology and Histopathology*, **2013**, 28, 691-9	1.4	13
199	Pulmonalarterielle Hypertonie bei angeborenen Herzfehlern: Problemstellung und Versorgungslage. *Deutsche Medizinische Wochenschrift*, **2013**, 138, e27-e27	0	
198	Effects of hypercapnia and NO synthase inhibition in sustained hypoxic pulmonary vasoconstriction. *Respiratory Research*, **2012**, 13, 7	7.3	17
197	Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study. *Journal of the American College of Cardiology*, **2012**, 60, 768-74	15.1	101
196	Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 897-908	10.2	219
195	Activation of TRPC6 channels is essential for lung ischaemia-reperfusion induced oedema in mice. *Nature Communications*, **2012**, 3, 649	17.4	137
194	Dynamic hyperinflation during exercise in patients with precapillary pulmonary hypertension. *Respiratory Medicine*, **2012**, 106, 308-13	4.6	25
193	HbA1c in pulmonary arterial hypertension: a marker of prognostic relevance?. *Journal of Heart and Lung Transplantation*, **2012**, 31, 1109-14	5.8	27
192	Safety and efficacy of exercise training in various forms of pulmonary hypertension. *European Respiratory Journal*, **2012**, 40, 84-92	13.6	158

191	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. *PLoS ONE*, **2012**, 7, e43433	3.7	89
190	Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. *Free Radical Biology and Medicine*, **2012**, 52, 1033-42	7.8	60
189	Cardiovocal Syndrome (Ortner's Syndrome) Associated with Chronic Thromboembolic Pulmonary Hypertension and Giant Pulmonary Artery Aneurysm: Case Report and Review of the Literature. *Case Reports in Medicine*, **2012**, 2012, 230736	0.7	15
188	Role of Src tyrosine kinases in experimental pulmonary hypertension. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 1354-65	9.4	90
187	Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 409-19	10.2	171
186	A case series of patients with severe pulmonary hypertension receiving an implantable pump for intravenous prostanoid therapy. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 1196-8	10.2	16
185	Left ventricular systolic dysfunction associated with pulmonary hypertension riociguat trial (LEPHT): rationale and design. *European Journal of Heart Failure*, **2012**, 14, 946-53	12.3	22
184	Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients. *European Respiratory Journal*, **2012**, 39, 119-24	13.6	41
183	PAR-2 inhibition reverses experimental pulmonary hypertension. *Circulation Research*, **2012**, 110, 1179-91	15.7	52
182	Effect of exercise and respiratory training on clinical progression and survival in patients with severe chronic pulmonary hypertension. *Respiration*, **2011**, 81, 394-401	3.7	125
181	Riociguat for the treatment of pulmonary hypertension. *Expert Opinion on Investigational Drugs*, **2011**, 20, 567-76	5.9	69
180	Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. *Cell*, **2011**, 147, 293-305	56.2	226
179	Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2011**, 30, 632-43	5.8	79
178	A retrospective review of long anterior fusions to the sacrum. *Spine Journal*, **2011**, 11, 290-4	4	10
177	Cologne Consensus Conference on pulmonary hypertension. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S1-2	3.2	4
176	Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S20-33	3.2	38
175	Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. *International Journal of Cardiology*, **2011**, 154 Suppl 1, S45-53	3.2	48
174	Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling. *PLoS ONE*, **2011**, 6, e18136	3.7	30

173	Psoas muscle architectural design, in vivo sarcomere length range, and passive tensile properties support its role as a lumbar spine stabilizer. *Spine*, **2011**, 36, E1666-74	3.3	35
172	Inflammation, immunological reaction and role of infection in pulmonary hypertension. *Clinical Microbiology and Infection*, **2011**, 17, 7-14	9.5	60
171	Stem cell-mediated natural tissue engineering. *Journal of Cellular and Molecular Medicine*, **2011**, 15, 52-63	3.6	10
170	Effects of riociguat in severe experimental pulmonary hypertension. *BMC Pharmacology*, **2011**, 11,		78
169	The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. *BMC Pharmacology*, **2011**, 11,		78
168	Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy. *BMC Pulmonary Medicine*, **2011**, 11, 56	3.5	13
167	Diacylglycerol regulates acute hypoxic pulmonary vasoconstriction via TRPC6. *Respiratory Research*, **2011**, 12, 20	7.3	44
166	Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. *Respiratory Research*, **2011**, 12, 60	7.3	53
165	Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension. *Respiratory Research*, **2011**, 12, 87	7.3	16
164	Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations. *Respiratory Research*, **2011**, 12, 99	7.3	47
163	Mechanisms of disease: pulmonary arterial hypertension. *Nature Reviews Cardiology*, **2011**, 8, 443-55	14.8	472
162	cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. *Circulation*, **2011**, 123, 1194-204	16.7	34
161	Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-*Pulmonary Circulation*, **2011**, 1, 259-68	2.7	38
160	Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. *European Respiratory Journal*, **2011**, 37, 1104-18	13.6	75
159	Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. *Chest*, **2011**, 140, 1274-1283	5.3	187
158	The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. *Science Translational Medicine*, **2011**, 3, 87ra53	17.5	50
157	Air travel can be safe and well tolerated in patients with clinically stable pulmonary hypertension. *Pulmonary Circulation*, **2011**, 1, 239-43	2.7	17
156	Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. *PLoS ONE*, **2011**, 6, e18883	3.7	33

155	Targeting non-malignant disorders with tyrosine kinase inhibitors. *Nature Reviews Drug Discovery*, **2010**, 9, 956-70	64.1	102
154	Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension. *European Respiratory Journal*, **2010**, 36, 808-18	13.6	43
153	Role of epidermal growth factor inhibition in experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 158-67	10.2	99
152	Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. *European Respiratory Journal*, **2010**, 36, 792-9	13.6	186
151	Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 182, 1171-7	10.2	276
150	Mitochondrial cytochrome redox states and respiration in acute pulmonary oxygen sensing. *European Respiratory Journal*, **2010**, 36, 1056-66	13.6	28
149	Diagnostik und Therapie der pulmonalen Hypertonie: Europ□sche Leitlinien 2009. *Deutsche Medizinische Wochenschrift*, **2010**, 135, e2-e15	0	0
148	Update on pulmonary hypertension 2009. *American Journal of Respiratory and Critical Care Medicine* , **2010**, 181, 1020-6	10.2	12
147	Animal models of pulmonary hypertension: role in translational research. *Drug Discovery Today: Disease Models*, **2010**, 7, 89-97	1.3	8
146	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. *Respiratory Research*, **2010**, 11, 146	7.3	17
145	Nebulization of the acidified sodium nitrite formulation attenuates acute hypoxic pulmonary vasoconstriction. *Respiratory Research*, **2010**, 11, 81	7.3	11
144	Burden of pulmonary arterial hypertension in Germany. *Respiratory Medicine*, **2010**, 104, 902-10	4.6	34
143	Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. *Respiratory Medicine*, **2010**, 104, 731-40	4.6	59
142	Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. *Journal of Molecular and Cellular Cardiology*, **2010**, 49, 598-605	5.8	47
141	Riociguat for pulmonary hypertension. *Future Cardiology*, **2010**, 6, 155-66	1.3	24
140	Targeting cancer with phosphodiesterase inhibitors. *Expert Opinion on Investigational Drugs*, **2010**, 19, 117-31	5.9	105
139	An evaluation of fracture stabilization comparing kyphoplasty and titanium mesh repair techniques for vertebral compression fractures: is bone cement necessary?. *Spine*, **2010**, 35, E768-73	3.3	20
138	Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH) **2010**,		2

137	Pulmonary hypertension: updated classification and management of pulmonary hypertension. *Heart*, **2010**, 96, 552-9	5.1	34
136	Aktuelle Therapie der pulmonal-arteriellen Hypertonie. *Pneumologe*, **2010**, 7, 192-199	0.1	
135	Diagnostik und Therapie der pulmonalen Hypertonie. *Kardiologe*, **2010**, 4, 189-207	0.6	3
134	Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. *Respiratory Physiology and Neurobiology*, **2010**, 174, 282-91	2.8	29
133	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. *BMC Pulmonary Medicine*, **2010**, 10, 26	3.5	29
132	Simvastatin as a treatment for pulmonary hypertension trial. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 1106-13	10.2	93
131	Classical transient receptor potential channel 6 (TRPC6) is essential for ischemia-reperfusion injury of the lung. *FASEB Journal*, **2010**, 24, 591.2	0.9	
130	Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. *Circulation*, **2009**, 119, 1747-57	16.7	164
129	Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. *Molecular Biology of the Cell*, **2009**, 20, 4751-65	3.5	73
128	Heme oxygenase-2 and large-conductance Ca2+-activated K+ channels: lung vascular effects of hypoxia. *American Journal of Respiratory and Critical Care Medicine*, **2009**, 180, 353-64	10.2	34
127	A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. *Circulation*, **2009**, 119, 2313-22	16.7	146
126	Effects of hypercapnia with and without acidosis on hypoxic pulmonary vasoconstriction. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 297, L977-83	5.8	57
125	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 297, L658-65	5.8	32
124	Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2009**, 296, L462-9	5.8	17
123	Inhibition of phosphodiesterase 4 enhances lung alveolarisation in neonatal mice exposed to hyperoxia. *European Respiratory Journal*, **2009**, 33, 861-70	13.6	39
122	Long-term outcome with intravenous iloprost in pulmonary arterial hypertension. *European Respiratory Journal*, **2009**, 34, 132-7	13.6	66
121	Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. *BMC Pharmacology*, **2009**, 9,		13
120	Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH). *BMC Pharmacology*, **2009**, 9,		2

119	The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies. *European Journal of Clinical Investigation*, **2009**, 39 Suppl 2, 38-49	4.6	38
118	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. *Pulmonary Pharmacology and Therapeutics*, **2009**, 22, 50-6	3.5	36
117	Noninvasive detection of early pulmonary vascular dysfunction in scleroderma. *Respiratory Medicine*, **2009**, 103, 1713-8	4.6	28
116	Future perspectives for the treatment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S108-S117	15.1	50
115	Updated evidence-based treatment algorithm in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, S78-S84	15.1	379
114	Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2009**, 54, 1971-81	15.1	191
113	Tadalafil therapy for pulmonary arterial hypertension. *Circulation*, **2009**, 119, 2894-903	16.7	769
112	Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. *European Respiratory Review*, **2009**, 18, 35-41	9.8	38
111	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. *European Respiratory Journal*, **2009**, 33, 785-92	13.6	186
110	Modulating cGMP to treat lung diseases. *Handbook of Experimental Pharmacology*, **2009**, 469-83	3.2	8
109	Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. *Journal of the American College of Cardiology*, **2008**, 52, 2127-34	15.1	409
108	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. *Pulmonary Pharmacology and Therapeutics*, **2008**, 21, 824-32	3.5	57
107	Regulation of hypoxic pulmonary vasoconstriction: basic mechanisms. *European Respiratory Journal*, **2008**, 32, 1639-51	13.6	152
106	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. *European Respiratory Journal*, **2008**, 32, 881-91	13.6	186
105	Prevention of pulmonary vascular and myocardial remodeling by the combined tyrosine and serine-/threonine kinase inhibitor, sorafenib, in pulmonary hypertension and right heart failure. *European Respiratory Review*, **2008**, 17, 72-73	9.8	
104	Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. *Circulation*, **2008**, 118, 1195-201	16.7	78
103	Fhl-1, a new key protein in pulmonary hypertension. *Circulation*, **2008**, 118, 1183-94	16.7	71
102	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. *European Respiratory Journal*, **2008**, 32, 198-209	13.6	101

101	Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation*, **2008**, 117, 3010-9	16.7	769
100	Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. *Circulation*, **2008**, 118, 2081-90	16.7	121
99	Pulmonary vascular disease in the developing world. *Circulation*, **2008**, 118, 1758-66	16.7	87
98	Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. *European Respiratory Journal*, **2008**, 31, 599-610	13.6	26
97	Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 188-96	10.2	66
96	Impairment of respiratory muscle function in pulmonary hypertension. *Clinical Science*, **2008**, 114, 165-71	6.5	58
95	The lectin-like domain of tumor necrosis factor-alpha improves alveolar fluid balance in injured isolated rabbit lungs. *Critical Care Medicine*, **2008**, 36, 1543-50	1.4	55
94	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. *BMC Pulmonary Medicine*, **2008**, 8, 25	3.5	31
93	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. *Respiratory Research*, **2007**, 8, 4	7.3	31
92	Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. *Circulation Research*, **2007**, 101, 258-67	15.7	279
91	Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2007**, 30, 922-7	13.6	127
90	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. *Circulation*, **2007**, 115, 2331-9	16.7	118
89	A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. *Cancer Research*, **2007**, 67, 5443-53	10.1	23
88	Microcirculatory dysfunction in the brain precedes changes in evoked potentials in endotoxin-induced sepsis syndrome in rats. *Cerebrovascular Diseases*, **2007**, 23, 140-7	3.2	49
87	Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. *European Respiratory Journal*, **2007**, 29, 713-9	13.6	59
86	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. *Respiratory Physiology and Neurobiology*, **2007**, 159, 196-201	2.8	28
85	Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide. *Respiratory Medicine*, **2007**, 101, 2125-32	4.6	24
84	Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. *American Journal of Respiratory Cell and Molecular Biology*, **2006**, 34, 505-13	5.7	83

83	Oxygen sensors in hypoxic pulmonary vasoconstriction. *Cardiovascular Research*, **2006**, 71, 620-9	9.9	49
82	Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies. *Cardiovascular Research*, **2006**, 72, 30-40	9.9	36
81	Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. *Circulation*, **2006**, 113, 286-95	16.7	183
80	Sildenafil treatment for portopulmonary hypertension. *European Respiratory Journal*, **2006**, 28, 563-7	13.6	168
79	Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. *Cerebrovascular Diseases*, **2006**, 21, 194-200	3.2	46
78	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 19093-8	11.5	247
77	Comparison of pharmacokinetics and vasodilatory effect of nebulized and infused iloprost in experimental pulmonary hypertension: rapid tolerance development. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2006**, 19, 353-63		13
76	Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. *Journal of the American College of Cardiology*, **2006**, 48, 1672-81	15.1	115
75	Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *Journal of the American College of Cardiology*, **2006**, 48, 2546-52	15.1	393
74	AMBRISENTAN HAS NO CLINICALLY RELEVANT EFFECT ON THE PHARMACOKINETICS OR PHARMACODYNAMICS OF WARFARIN. *Chest*, **2006**, 130, 256S	5.3	13
73	Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. *Annals of Internal Medicine*, **2006**, 144, 149-50	8	27
72	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. *Nature Reviews Drug Discovery*, **2006**, 5, 689-702	64.1	366
71	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. *Thrombosis and Haemostasis*, **2006**, 95, 720-727	7	20
70	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. *Thrombosis and Haemostasis*, **2006**, 95, 720-7	7	6
69	Hypoxic pulmonary vasoconstriction--triggered by an increase in reactive oxygen species?. *Novartis Foundation Symposium*, **2006**, 272, 196-208; discussion 208-17		7
68	Sildenafil citrate therapy for pulmonary arterial hypertension. *New England Journal of Medicine*, **2005**, 353, 2148-57	59.2	1843
67	Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration. *Respiratory Research*, **2005**, 6, 128	7.3	29
66	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. *Respiratory Research*, **2005**, 6, 76	7.3	25

65	Detection of reactive oxygen species in isolated, perfused lungs by electron spin resonance spectroscopy. *Respiratory Research*, **2005**, 6, 86	7.3	27
64	Imatinib for the treatment of pulmonary arterial hypertension. *New England Journal of Medicine*, **2005**, 353, 1412-3	59.2	377
63	Congenital erythropoietin over-expression causes "anti-pulmonary hypertensive" structural and functional changes in mice, both in normoxia and hypoxia. *Thrombosis and Haemostasis*, **2005**, 94, 630-8	7	29
62	Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. *FASEB Journal*, **2005**, 19, 1175-7	0.9	144
61	Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 358-63	10.2	55
60	Thrombin impairs alveolar fluid clearance by promoting endocytosis of Na+,K+-ATPase. *American Journal of Respiratory Cell and Molecular Biology*, **2005**, 33, 343-54	5.7	56
59	Oleic acid inhibits alveolar fluid reabsorption: a role in acute respiratory distress syndrome?. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 469-79	10.2	68
58	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. *Current Topics in Developmental Biology*, **2005**, 67, 251-84	5.3	8
57	Reversal of experimental pulmonary hypertension by PDGF inhibition. *Journal of Clinical Investigation*, **2005**, 115, 2811-21	15.9	764
56	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 39-45	10.2	207
55	Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. *Circulation Research*, **2004**, 94, 1101-8	15.7	86
54	Measurement of exhaled hydrogen peroxide from rabbit lungs. *Biological Chemistry*, **2004**, 385, 259-64	4.5	7
53	Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. *European Respiratory Journal*, **2004**, 23, 321-6	13.6	58
52	Prostacyclin and its analogues in the treatment of pulmonary hypertension **2004**, 102, 139-53		102
51	Increase in alveolar antioxidant levels in hyperoxic and anoxic ventilated rabbit lungs during ischemia. *Free Radical Biology and Medicine*, **2004**, 36, 78-89	7.8	13
50	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. *Free Radical Biology and Medicine*, **2004**, 36, 1279-88	7.8	156
49	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2004**, 43, 68S-72S	15.1	108
48	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. *Journal of the American College of Cardiology*, **2004**, 44, 1488-96	15.1	86

47	Basic features of hypoxic pulmonary vasoconstriction in mice. *Respiratory Physiology and Neurobiology*, **2004**, 139, 191-202	2.8	51
46	Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. *Annals of Internal Medicine*, **2004**, 141, 169-77	8	220
45	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension **2004**, 163-168		
44	Zardaverine and aerosolised iloprost in a model of acute respiratory failure. *European Respiratory Journal*, **2003**, 22, 342-7	13.6	18
43	Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. *American Journal of Physiology - Heart and Circulatory Physiology*, **2003**, 284, H931-8	5.2	29
42	Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2003**, 167, 1139-41	10.2	211
41	Effects of mitochondrial inhibitors and uncouplers on hypoxic vasoconstriction in rabbit lungs. *American Journal of Respiratory Cell and Molecular Biology*, **2003**, 29, 721-32	5.7	50
40	Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. *Chest*, **2003**, 124, 1294-304	5.3	100
39	Subthreshold doses of nebulized prostacyclin and rolipram synergistaically protect against lung ischemia-reperfusion. *Transplantation*, **2003**, 75, 814-21	1.8	6
38	Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost. *Thrombosis and Haemostasis*, **2003**, 90, 1141-9	7	36
37	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. *Journal of the American College of Cardiology*, **2003**, 42, 158-64	15.1	290
36	Sildenafil for lung fibrosis and pulmonary hypertension. *Lancet, The*, **2003**, 361, 263	40	
35	Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: responders versus nonresponders. *European Respiratory Journal*, **2002**, 19, 664-71	13.6	20
34	Pharmacokinetics and metabolism of infused versus inhaled iloprost in isolated rabbit lungs. *Journal of Pharmacology and Experimental Therapeutics*, **2002**, 303, 741-5	4.7	20
33	Apical, but not basolateral, endotoxin preincubation protects alveolar epithelial cells against hydrogen peroxide-induced loss of barrier function: the role of nitric oxide synthesis. *Journal of Immunology*, **2002**, 169, 1474-81	5.3	16
32	Inhaled iloprost for severe pulmonary hypertension. *New England Journal of Medicine*, **2002**, 347, 322-9	59.2	1308
31	Nocturnal periodic breathing in primary pulmonary hypertension. *European Respiratory Journal*, **2002**, 19, 658-63	13.6	67
30	Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. *Annals of Internal Medicine*, **2002**, 136, 515-22	8	346

29	Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. *Critical Care Medicine*, **2002**, 30, 2489-92	1.4	62
28	Mediator generation and signaling events in alveolar epithelial cells attacked by S. aureus alpha-toxin. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2002**, 282, L207-14	5.8	51
27	Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. *Lancet, The*, **2002**, 360, 895-900	40	590
26	Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. *European Respiratory Journal*, **2001**, 17, 14-9	13.6	79
25	Cellular pathophysiology and therapy of pulmonary hypertension. *Translational Research*, **2001**, 138, 367-77		48
24	Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. *American Journal of Respiratory and Critical Care Medicine*, **2001**, 164, 1694-700	10.2	49
23	Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. *American Journal of Respiratory Cell and Molecular Biology*, **2001**, 25, 219-25	5.7	20
22	Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: response to iloprost inhalation. *Journal of the American College of Cardiology*, **2001**, 38, 1130-6	15.1	47
21	NO and reactive oxygen species are involved in biphasic hypoxic vasoconstriction of isolated rabbit lungs. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L638-45	5.8	53
20	Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L792-800	5.8	15
19	Alveolar epithelial barrier functions in ventilated perfused rabbit lungs. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L896-904	5.8	19
18	Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 281, L1361-8	5.8	30
17	Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)?. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2000**, 279, L683-90	5.8	75
16	Schwere pulmonale Hypertonie - Vasodilative Therapie in der Lungenstrombahn. *Pneumologie*, **2000**, 54, 160-169	0.5	
15	Nitric oxide (NO)-dependent but not NO-independent guanylate cyclase activation attenuates hypoxic vasoconstriction in rabbit lungs. *American Journal of Respiratory Cell and Molecular Biology*, **2000**, 23, 222-7	5.7	22
14	Differential impact of ultrasonically nebulized versus tracheal-instilled surfactant on ventilation-perfusion (VA/Q) mismatch in a model of acute lung injury. *American Journal of Respiratory and Critical Care Medicine*, **2000**, 161, 152-9	10.2	27
13	A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. *Journal of the American College of Cardiology*, **2000**, 35, 176-82	15.1	246
12	Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **1999**, 276, L90-5	5.8	33

11	Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 160, 1500-6	10.2	68
10	Prostacyclin enhances stretch-induced surfactant secretion in alveolar epithelial type II cells. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 160, 846-51	10.2	34
9	Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **1999**, 160, 600-7	10.2	300
8	Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. *Intensive Care Medicine*, **1998**, 24, 631-4	14.5	49
7	Cyclooxygenase isoenzyme localization and mRNA expression in rat lungs. *American Journal of Respiratory Cell and Molecular Biology*, **1998**, 18, 479-88	5.7	69
6	Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 154, 57-62	10.2	147
5	Synergism of alveolar endotoxin "priming" and intravascular exotoxin challenge in lung injury. *American Journal of Respiratory and Critical Care Medicine*, **1996**, 154, 460-8	10.2	8
4	Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. *Annals of Internal Medicine* , **1996**, 124, 820-4	8	273
3	Endotoxin "priming" potentiates lung vascular abnormalities in response to Escherichia coli hemolysin: an example of synergism between endo- and exotoxin. *Journal of Experimental Medicine*, **1994**, 180, 1437-43	16.6	26
2	Hypoxic Pulmonary Vasoconstriction□riggered by an Increase in Reactive Oxygen Species?. *Novartis Foundation Symposium*,196-213		8
1	Phosphodiesterase-5 Inhibitors in Pulmonary Arterial Hypertension105-125		1